Incyte (INCY) Equity Income (2017 - 2026)
Incyte (INCY) reported Equity Income of $6.6 million for Q1 2026, up 590.77% on a YoY basis from $954156.8 in Q1 2025, and down 63.88% quarter-over-quarter from $18.2 million in Q4 2025.
Incyte (INCY) Equity Income (2017 - 2026) Analysis & Trends
Incyte has reported Equity Income for 10 years, with the latest figure at $6.6 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Income rose 590.77% year-over-year to $6.6 million; the trailing twelve-month figure through Mar 2026 stood at $29.2 million (up 98.47% YoY), and the FY2025 full-year result was $21.3 million, down 81.63% from the prior year.
- Equity Income for Q1 2026 stood at $6.6 million, down from $18.2 million in the prior quarter.
- The five-year high for Equity Income was $99.9 million in Q1 2024, with the low at -$46.6 million in Q1 2022.
- Historically, Equity Income has averaged $5.9 million across 5 years, with a median of -$1.3 million in 2025.
- Annual changes were most pronounced in 2023 — Equity Income sank 3938.48% — and 2024, when it soared 1979.41%.
- Incyte's Equity Income stood at -$15.4 million in 2022, then jumped by 320.44% to $34.1 million in 2023, then plunged by 129.9% to -$10.2 million in 2024, then surged by 279.22% to $18.2 million in 2025, then plunged by 63.88% to $6.6 million in 2026.
- The last three Equity Income figures came in at $6.6 million (Q1 2026), $18.2 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 6.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.59 Mn |
| Dec 31, 2025 | 18.25 Mn |
| Sep 30, 2025 | 8.56 Mn |
| Jun 30, 2025 | -4.15 Mn |
| Mar 31, 2025 | -1.34 Mn |
| Dec 31, 2024 | -10.18 Mn |
| Sep 30, 2024 | -12.98 Mn |
| Jun 30, 2024 | 39.24 Mn |
| Mar 31, 2024 | 99.95 Mn |
| Dec 31, 2023 | 34.05 Mn |
| Sep 30, 2023 | -26.65 Mn |
| Jun 30, 2023 | 41.81 Mn |
| Mar 31, 2023 | -5.32 Mn |
| Dec 31, 2022 | -15.45 Mn |
| Sep 30, 2022 | -660,000.00 |
| Jun 30, 2022 | -24.90 Mn |
| Mar 31, 2022 | -46.59 Mn |
| Dec 31, 2021 | 4.32 Mn |
| Sep 30, 2021 | -27.45 Mn |
| Jun 30, 2021 | 26.77 Mn |